Recommendations  ||| S:0 E:16 ||| NNS
for  ||| S:16 E:20 ||| IN
the  ||| S:20 E:24 ||| DT
conduct  ||| S:24 E:32 ||| NN
of  ||| S:32 E:35 ||| IN
clinical  ||| S:35 E:44 ||| JJ
trials  ||| S:44 E:51 ||| NNS
for  ||| S:51 E:55 ||| IN
drugs  ||| S:55 E:61 ||| NNS
to  ||| S:61 E:64 ||| TO
treat  ||| S:64 E:70 ||| VB
or  ||| S:70 E:73 ||| CC
prevent  ||| S:73 E:81 ||| VB
sarcopenia  ||| S:81 E:92 ||| JJ
Sarcopenia  ||| S:92 E:103 ||| NNP
is  ||| S:103 E:106 ||| VBZ
an  ||| S:106 E:109 ||| DT
age-related  ||| S:109 E:121 ||| JJ
muscle  ||| S:121 E:128 ||| NN
condition  ||| S:128 E:138 ||| NN
which  ||| S:138 E:144 ||| WDT
is  ||| S:144 E:147 ||| VBZ
frequently  ||| S:147 E:158 ||| RB
a  ||| S:158 E:160 ||| DT
precursor  ||| S:160 E:170 ||| NN
of  ||| S:170 E:173 ||| IN
frailty ||| S:173 E:180 ||| NN
,  ||| S:180 E:182 ||| ,
mobility  ||| S:182 E:191 ||| JJ
disability  ||| S:191 E:202 ||| NN
and  ||| S:202 E:206 ||| CC
premature  ||| S:206 E:216 ||| JJ
death ||| S:216 E:221 ||| NN
.  ||| S:221 E:223 ||| .
It  ||| S:223 E:226 ||| PRP
has  ||| S:226 E:230 ||| VBZ
a  ||| S:230 E:232 ||| DT
high  ||| S:232 E:237 ||| JJ
prevalence  ||| S:237 E:248 ||| NN
in  ||| S:248 E:251 ||| IN
older  ||| S:251 E:257 ||| JJR
populations  ||| S:257 E:269 ||| NNS
and  ||| S:269 E:273 ||| CC
presents  ||| S:273 E:282 ||| VBZ
a  ||| S:282 E:284 ||| DT
considerable  ||| S:284 E:297 ||| JJ
social  ||| S:297 E:304 ||| JJ
and  ||| S:304 E:308 ||| CC
economic  ||| S:308 E:317 ||| JJ
burden ||| S:317 E:323 ||| NN
.  ||| S:323 E:325 ||| .
Potential  ||| S:325 E:335 ||| JJ
treatments  ||| S:335 E:346 ||| NNS
are  ||| S:346 E:350 ||| VBP
under  ||| S:350 E:356 ||| IN
development  ||| S:356 E:368 ||| NN
but ||| S:368 E:371 ||| CC
,  ||| S:371 E:373 ||| ,
as  ||| S:373 E:376 ||| RB
yet ||| S:376 E:379 ||| RB
,  ||| S:379 E:381 ||| ,
no  ||| S:381 E:384 ||| DT
guidelines  ||| S:384 E:395 ||| NNS
support  ||| S:395 E:403 ||| VBP
regulatory  ||| S:403 E:414 ||| JJ
studies  ||| S:414 E:422 ||| NNS
for  ||| S:422 E:426 ||| IN
new  ||| S:426 E:430 ||| JJ
drugs  ||| S:430 E:436 ||| NNS
to  ||| S:436 E:439 ||| TO
manage  ||| S:439 E:446 ||| VB
sarcopenia ||| S:446 E:456 ||| NNS
.  ||| S:456 E:458 ||| .
The  ||| S:458 E:462 ||| DT
objective  ||| S:462 E:472 ||| NN
of  ||| S:472 E:475 ||| IN
this  ||| S:475 E:480 ||| DT
position  ||| S:480 E:489 ||| NN
paper  ||| S:489 E:495 ||| NN
is  ||| S:495 E:498 ||| VBZ
therefore  ||| S:498 E:508 ||| RB
to  ||| S:508 E:511 ||| TO
suggest  ||| S:511 E:519 ||| VB
a  ||| S:519 E:521 ||| DT
set  ||| S:521 E:525 ||| NN
of  ||| S:525 E:528 ||| IN
potential  ||| S:528 E:538 ||| JJ
endpoints  ||| S:538 E:548 ||| NN
and  ||| S:548 E:552 ||| CC
target  ||| S:552 E:559 ||| NN
population  ||| S:559 E:570 ||| NN
definitions  ||| S:570 E:582 ||| NNS
to  ||| S:582 E:585 ||| TO
stimulate  ||| S:585 E:595 ||| VB
debate  ||| S:595 E:602 ||| NN
and  ||| S:602 E:606 ||| CC
progress  ||| S:606 E:615 ||| NN
within  ||| S:615 E:622 ||| IN
the  ||| S:622 E:626 ||| DT
medico-scientific  ||| S:626 E:644 ||| JJ
and  ||| S:644 E:648 ||| CC
regulatory  ||| S:648 E:659 ||| JJ
communities ||| S:659 E:670 ||| NNS
.  ||| S:670 E:672 ||| .
A  ||| S:672 E:674 ||| DT
multidisciplinary  ||| S:674 E:692 ||| JJ
expert  ||| S:692 E:699 ||| NN
working  ||| S:699 E:707 ||| VBG
group  ||| S:707 E:713 ||| NN
was  ||| S:713 E:717 ||| VBD
hosted  ||| S:717 E:724 ||| VBN
by  ||| S:724 E:727 ||| IN
the  ||| S:727 E:731 ||| DT
European  ||| S:731 E:740 ||| NNP
Society  ||| S:740 E:748 ||| NNP
for  ||| S:748 E:752 ||| IN
Clinical  ||| S:752 E:761 ||| NNP
and  ||| S:761 E:765 ||| CC
Economic  ||| S:765 E:774 ||| NNP
Aspects  ||| S:774 E:782 ||| NNP
of  ||| S:782 E:785 ||| IN
Osteoporosis  ||| S:785 E:798 ||| NNP
and  ||| S:798 E:802 ||| CC
Osteoarthritis ||| S:802 E:816 ||| NNP
,  ||| S:816 E:818 ||| ,
which  ||| S:818 E:824 ||| WDT
reviewed  ||| S:824 E:833 ||| VBD
and  ||| S:833 E:837 ||| CC
discussed  ||| S:837 E:847 ||| VBD
the  ||| S:847 E:851 ||| DT
recent  ||| S:851 E:858 ||| JJ
literature  ||| S:858 E:869 ||| NN
from  ||| S:869 E:874 ||| IN
a  ||| S:874 E:876 ||| DT
perspective  ||| S:876 E:888 ||| NN
of  ||| S:888 E:891 ||| IN
clinical  ||| S:891 E:900 ||| JJ
experience  ||| S:900 E:911 ||| NN
and  ||| S:911 E:915 ||| CC
guideline  ||| S:915 E:925 ||| NN
development ||| S:925 E:936 ||| NN
.  ||| S:936 E:938 ||| .
Relevant  ||| S:938 E:947 ||| JJ
parallels  ||| S:947 E:957 ||| NNS
were  ||| S:957 E:962 ||| VBD
drawn  ||| S:962 E:968 ||| VBN
from  ||| S:968 E:973 ||| IN
the  ||| S:973 E:977 ||| DT
development  ||| S:977 E:989 ||| NN
of  ||| S:989 E:992 ||| IN
definition  ||| S:992 E:1003 ||| NN
of  ||| S:1003 E:1006 ||| IN
osteoporosis  ||| S:1006 E:1019 ||| NN
as  ||| S:1019 E:1022 ||| IN
a  ||| S:1022 E:1024 ||| DT
disease  ||| S:1024 E:1032 ||| NN
and  ||| S:1032 E:1036 ||| CC
clinical  ||| S:1036 E:1045 ||| JJ
assessment  ||| S:1045 E:1056 ||| NN
of  ||| S:1056 E:1059 ||| IN
pharmaceutical  ||| S:1059 E:1074 ||| JJ
treatments  ||| S:1074 E:1085 ||| NNS
for  ||| S:1085 E:1089 ||| IN
that  ||| S:1089 E:1094 ||| DT
indication ||| S:1094 E:1104 ||| NN
.  ||| S:1104 E:1106 ||| .
A  ||| S:1106 E:1108 ||| DT
case-finding  ||| S:1108 E:1121 ||| JJ
decision  ||| S:1121 E:1130 ||| NN
tree  ||| S:1130 E:1135 ||| NN
is  ||| S:1135 E:1138 ||| VBZ
briefly  ||| S:1138 E:1146 ||| RB
reviewed  ||| S:1146 E:1155 ||| VBN
with  ||| S:1155 E:1160 ||| IN
a  ||| S:1160 E:1162 ||| DT
discussion  ||| S:1162 E:1173 ||| NN
of  ||| S:1173 E:1176 ||| IN
recent  ||| S:1176 E:1183 ||| JJ
prevalence  ||| S:1183 E:1194 ||| JJ
estimations  ||| S:1194 E:1206 ||| NN
of  ||| S:1206 E:1209 ||| IN
different  ||| S:1209 E:1219 ||| JJ
relevant  ||| S:1219 E:1228 ||| JJ
threshold  ||| S:1228 E:1238 ||| NN
values ||| S:1238 E:1244 ||| NNS
.  ||| S:1244 E:1246 ||| .
The  ||| S:1246 E:1250 ||| DT
selection  ||| S:1250 E:1260 ||| NN
criteria  ||| S:1260 E:1269 ||| NNS
for  ||| S:1269 E:1273 ||| IN
patients  ||| S:1273 E:1282 ||| NNS
in  ||| S:1282 E:1285 ||| IN
regulatory  ||| S:1285 E:1296 ||| JJ
studies  ||| S:1296 E:1304 ||| NNS
are  ||| S:1304 E:1308 ||| VBP
discussed  ||| S:1308 E:1318 ||| VBN
according  ||| S:1318 E:1328 ||| VBG
to  ||| S:1328 E:1331 ||| TO
the  ||| S:1331 E:1335 ||| DT
aims  ||| S:1335 E:1340 ||| NNS
of  ||| S:1340 E:1343 ||| IN
the  ||| S:1343 E:1347 ||| DT
investigation  ||| S:1347 E:1361 ||| NN
( ||| S:1361 E:1362 ||| -LRB-
sarcopenia  ||| S:1362 E:1373 ||| JJ
prevention  ||| S:1373 E:1384 ||| NN
or  ||| S:1384 E:1387 ||| CC
treatment ||| S:1387 E:1396 ||| NN
)  ||| S:1396 E:1398 ||| -RRB-
and  ||| S:1398 E:1402 ||| CC
the  ||| S:1402 E:1406 ||| DT
stage  ||| S:1406 E:1412 ||| NN
of  ||| S:1412 E:1415 ||| IN
project  ||| S:1415 E:1423 ||| NN
development ||| S:1423 E:1434 ||| NN
.  ||| S:1434 E:1436 ||| .
The  ||| S:1436 E:1440 ||| DT
possible  ||| S:1440 E:1449 ||| JJ
endpoints  ||| S:1449 E:1459 ||| NN
of  ||| S:1459 E:1462 ||| IN
such  ||| S:1462 E:1467 ||| JJ
studies  ||| S:1467 E:1475 ||| NNS
are  ||| S:1475 E:1479 ||| VBP
reviewed  ||| S:1479 E:1488 ||| VBN
and  ||| S:1488 E:1492 ||| CC
a  ||| S:1492 E:1494 ||| DT
plea  ||| S:1494 E:1499 ||| NN
is  ||| S:1499 E:1502 ||| VBZ
made  ||| S:1502 E:1507 ||| VBN
for  ||| S:1507 E:1511 ||| IN
the  ||| S:1511 E:1515 ||| DT
establishment  ||| S:1515 E:1529 ||| NN
of  ||| S:1529 E:1532 ||| IN
a  ||| S:1532 E:1534 ||| DT
core  ||| S:1534 E:1539 ||| NN
outcome  ||| S:1539 E:1547 ||| NN
set  ||| S:1547 E:1551 ||| VBN
to  ||| S:1551 E:1554 ||| TO
be  ||| S:1554 E:1557 ||| VB
used  ||| S:1557 E:1562 ||| VBN
in  ||| S:1562 E:1565 ||| IN
all  ||| S:1565 E:1569 ||| DT
clinical  ||| S:1569 E:1578 ||| JJ
trials  ||| S:1578 E:1585 ||| NNS
of  ||| S:1585 E:1588 ||| IN
sarcopenia ||| S:1588 E:1598 ||| NN
.  ||| S:1598 E:1600 ||| .
The  ||| S:1600 E:1604 ||| DT
current  ||| S:1604 E:1612 ||| JJ
lack  ||| S:1612 E:1617 ||| NN
of  ||| S:1617 E:1620 ||| IN
guidelines  ||| S:1620 E:1631 ||| NNS
for  ||| S:1631 E:1635 ||| IN
the  ||| S:1635 E:1639 ||| DT
assessment  ||| S:1639 E:1650 ||| NN
of  ||| S:1650 E:1653 ||| IN
new  ||| S:1653 E:1657 ||| JJ
therapeutic  ||| S:1657 E:1669 ||| JJ
treatments  ||| S:1669 E:1680 ||| NNS
for  ||| S:1680 E:1684 ||| IN
sarcopenia  ||| S:1684 E:1695 ||| NNS
could  ||| S:1695 E:1701 ||| MD
potentially  ||| S:1701 E:1713 ||| RB
hinder  ||| S:1713 E:1720 ||| VB
the  ||| S:1720 E:1724 ||| DT
delivery  ||| S:1724 E:1733 ||| NN
of  ||| S:1733 E:1736 ||| IN
effective  ||| S:1736 E:1746 ||| JJ
medicines  ||| S:1746 E:1756 ||| NNS
to  ||| S:1756 E:1759 ||| TO
patients  ||| S:1759 E:1768 ||| NNS
at  ||| S:1768 E:1771 ||| IN
risk ||| S:1771 E:1775 ||| NN
.  ||| S:1775 E:1777 ||| .
